Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BComparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoringClinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia AUse of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.Monitoring rFVIII prophylaxis dosing using global haemostasis assays.Optimizing outcomes for patients with severe haemophilia A.Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Secondary prophylaxis with factor IX concentrates: continuous infusion.Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.Pharmacotherapy of haemophilia A.Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.The role of Rixubis™ in the treatment of hemophilia B.Methods for individualising factor VIII dosing in prophylaxis.Emerging drugs for hemophilia B.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.Longer-acting clotting factor concentrates for hemophilia.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Measurement of factor VIII pharmacokinetics in routine clinical practice.Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.
P2860
Q28078281-CC3AFFA9-B9C9-4D09-A002-6CED0F08F70CQ33794432-3BAC6498-0EB3-4B2C-88AC-2D0B21558676Q34045763-FCF2E4C1-72AD-4F1C-A562-F2D7E54BFE2BQ34557556-19161217-FB2B-43A8-85A1-186C89D2F87BQ35692016-A3DB19E5-69C4-4DFE-BAC3-FBC21931FDBEQ36000862-F4230DF8-ADAF-498A-A2D0-504B74DD98E6Q36291059-3E78091C-0DE6-49E3-A973-31C5C9F5608DQ36383257-7F2B3A2F-8821-4486-9062-814AF5D6586EQ36788113-60F16B60-1DB4-4317-8CA1-5B83B88262A3Q36932769-B0E0937D-8C48-4D82-9941-3D021794BCFBQ37057618-0EDA2D55-0FCD-4C99-B50F-764DE4B6EBC9Q37357215-93670B1E-D036-40EA-A9AB-86F0E20F4DCFQ37686530-5CEE142F-A005-4598-BDB0-A6F33FF54E97Q37891089-B4FF390E-6A3F-40E1-9F7F-D5184A2A3928Q38115812-6C1E7B71-A6F6-43E8-9166-C87DC6D6A5F1Q38205211-ACAD69ED-6BCA-4C97-8CF5-9C620E40B8F2Q38210808-DA49D784-40A0-4D99-AB29-B4CE907F8013Q38222572-28E339EE-CA26-4A2D-B351-B78430A6A5A3Q38237476-E3EC24E3-1736-4F23-9BB9-0009C3EC2617Q38266890-A2888D29-6DEC-4E5E-81EC-47AD9828BFE3Q38543283-4BF537BF-8154-4016-9CE5-D53B6E526E25Q38944641-A006BC77-D950-4C1C-80F2-B0C5B3516595Q39952685-8792579F-9A8A-414A-8F2A-5CBFE0851344Q39957037-5B517810-C3BE-4DF7-961B-EB3587BC353FQ40066317-57F88E75-7C2F-41F6-A1BA-FEB6DE35A436Q42693839-65C3D5F4-953B-43F1-BE74-578885395FCAQ44051815-45E1C95C-3A02-4E2E-AAB9-F78CD305D9A5Q44566231-7F7616EC-A754-44C2-9865-9355E46D75FAQ45862229-8C275407-62D4-4324-BA79-EECE5B97DB75Q45862449-442086CD-BAC4-4157-8063-B1CE296A38A4Q45864852-2E6AF563-523A-483F-AFBE-EE5244514A8EQ45866870-C5077ECA-468D-4AF1-8129-F00ECE9A3FB8Q45868331-05327532-D142-4888-9960-437588C74181Q45868800-6C52456A-0D02-43CA-AB44-FC05B09DC7A7Q45869569-E579085E-F5F2-4F1F-8253-B795C74F353EQ45869919-1C9B235E-6B3B-47C4-90F1-D69BA140AEC7Q45871529-A74ADD87-C5C6-4A22-902A-4C61AFBB4399Q45873192-D75C5689-9013-4261-A93C-5EFDC9407BE8Q45875327-79D6CBD9-5399-45CD-946A-D2BA248BD169Q45876681-C7112AE4-3238-4D9B-85E4-C84D09ADF4CE
P2860
Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@ast
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@en
type
label
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@ast
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@en
prefLabel
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@ast
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@en
P2860
P1433
P1476
Prophylactic dosing of factor ...... l pharmacokinetic perspective.
@en
P2093
Björkman S
P2860
P304
101-8; discussion 109-10
P356
10.1046/J.1365-2516.9.S1.4.X
P478
P577
2003-05-01T00:00:00Z